This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
This is the net price. Taxes to be calculated in checkout.
Shiroiwa T, Fukuda T, Shimozuma K, Ohashi Y, Tsutani K.Cost-effectiveness analysis of capecitabine compared with bolus 5-fluorouracil/l-leucovorin for the adjuvant treatment of colon cancer in Japan. PharmacoEconomics 27: 597-608, No. 7, 2009
About this article
Cite this article
Capecitabine dominant over fluorouracil/levofolinate in Japan. Pharmacoecon. Outcomes News 586, 6 (2009). https://doi.org/10.2165/00151234-200905860-00014
- Colon Cancer
- Probabilistic Sensitivity Analysis
- Healthcare Payer
- Oral Capecitabine